IRX 5183

Drug Profile

IRX 5183

Alternative Names: AGN 195183; NRX 195183; VTP 195183

Latest Information Update: 14 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Allergan
  • Developer Io Therapeutics
  • Class Antineoplastics; Antipsoriatics
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Psoriasis
  • Discontinued Stem cell mobilisation

Most Recent Events

  • 14 May 2016 Phase-I/II development for Cancer is ongoing in USA (PO)
  • 22 Apr 2016 Sidney Kimmel Comprehensive Cancer Center plans a phase I/II trial for Acute myeloid leukaemia, Myelodysplastic syndrome and Chronic myelomonocytic leukaemia (Second-line therapy or greater) in USA (PO) (NCT02749708)
  • 06 Oct 2011 Clinical trials in Psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top